• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications are not effective for a lot of patients suffering from depression. A customized treatment may be the solution.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into personalized micro-interventions that improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and uncover distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 However, only half of people suffering from the condition receive treatment1. To improve the outcomes, doctors must be able to identify and treat patients who are most likely to respond to specific treatments.

Personalized depression treatment is one method to achieve this. By using sensors on mobile phones as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover biological and behavioral factors that predict response.

The majority of research done to the present has been focused on sociodemographic and clinical characteristics. These include demographic factors such as age, sex and educational level, clinical characteristics like the severity of symptoms and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these factors can be predicted from the data in medical records, only a few studies have utilized longitudinal data to explore the factors that influence mood in people. Few studies also take into account the fact that moods can be very different between individuals. Therefore, it is crucial to develop methods that permit the determination of individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can identify different patterns of behavior and emotions that vary between individuals.

The team also devised a machine learning algorithm to model dynamic predictors for the mood of each person's depression. The algorithm combines these personal differences into a unique "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. The correlation was low however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied greatly between individuals.

Predictors of Symptoms

Depression is the most common cause of disability around the world1, but it is often not properly diagnosed and treated. In addition, a lack of effective interventions and stigmatization associated with depression disorders hinder many individuals from seeking help.

To help with personalized treatment, it what is the best treatment for anxiety and depression important to identify predictors of symptoms. However, the methods used to predict symptoms depend on the clinical interview which is not reliable and only detects a small number of features that are associated with depression.2

Machine learning can improve the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can be used to provide a wide range of unique behaviors and activities, which are difficult to record through interviews, and allow for high-resolution, continuous measurements.

The study involved University of California Los Angeles (UCLA) students with mild to severe depression symptoms. who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical treatment in accordance with their severity of depression. Those with a CAT-DI score of 35 or 65 were given online support with the help of a coach. Those with a score 75 were sent to in-person clinics for psychotherapy.

At baseline, participants provided an array of questions regarding their personal demographics and psychosocial characteristics. The questions covered age, sex, and education, marital status, financial status and whether they were divorced or not, their current suicidal thoughts, intent or attempts, as well as the frequency with which they consumed alcohol. Participants also scored their level of perimenopause depression treatment symptom severity on a scale ranging from 0-100 using the CAT-DI. CAT-DI assessments were conducted every week for those that received online support, and once a week for those receiving in-person support.

Predictors of electric treatment for depression Response

Research is focusing on personalization of depression treatment. Many studies are aimed at finding predictors, which can aid clinicians in identifying the most effective medications to treat each individual. In particular, pharmacogenetics identifies genetic variations that affect how the body's metabolism reacts to antidepressants. This lets doctors choose the medications that are likely to be the most effective for each patient, while minimizing time and effort spent on trial-and error treatments and eliminating any adverse consequences.

Another approach that is promising is to create prediction models combining the clinical data with neural imaging data. These models can be used to identify the variables that are most likely to predict a specific outcome, like whether a medication will improve mood or symptoms. These models can be used to determine the patient's response to a treatment, allowing doctors maximize the effectiveness.

A new type of research uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables to improve predictive accuracy. These models have proven to be useful for forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming more popular in psychiatry and will likely become the standard of future medical practice.

In addition to ML-based prediction models, research into the mechanisms that cause depression is continuing. Recent research suggests that the disorder is associated with neural dysfunctions that affect specific circuits. This suggests that an individualized treatment for depression will be based upon targeted therapies that restore normal function to these circuits.

One method to achieve this is through internet-delivered interventions that offer a more individualized and tailored experience for patients. One study found that an internet-based program helped improve symptoms and improved quality life for MDD patients. Furthermore, a randomized controlled study of a personalised approach to treating depression showed sustained improvement and reduced side effects in a significant proportion of participants.

Predictors of side effects

A major challenge in personalized depression best Natural Treatment for depression involves identifying and predicting which antidepressant medications will have the least amount of side effects or none at all. Many patients take a trial-and-error approach, with a variety of medications prescribed before finding one that is safe and effective. Pharmacogenetics offers a fresh and exciting method of selecting antidepressant drugs that are more effective and specific.

There are many predictors that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of patients like gender or ethnicity, and comorbidities. However finding the most reliable and reliable predictive factors for a specific treatment is likely to require randomized controlled trials of considerably larger samples than those normally enrolled in clinical trials. This is because it may be more difficult to identify moderators or interactions in trials that only include a single episode per person instead of multiple episodes over time.

Furthermore, the estimation of a patient's response to a particular medication will also likely need to incorporate information regarding symptoms and comorbidities as well as the patient's previous experiences with the effectiveness and tolerability of the medication. Currently, only a few easily identifiable sociodemographic variables and clinical variables seem to be reliable in predicting the response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics in depression treatment is still in its beginning stages, and many challenges remain. It is crucial to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression, as well as a clear definition of a reliable predictor of treatment response. Ethics such as privacy and the ethical use of genetic information should also be considered. In the long run the use of pharmacogenetics could offer a chance to lessen the stigma that surrounds mental health care and improve the treatment outcomes for patients with depression. But, like any other psychiatric treatment, careful consideration and implementation is necessary. At present, the most effective option is to provide patients with various effective medications for depression and encourage them to speak freely with their doctors about their experiences and concerns.